This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
genetics: Archive
5 Top-Performing ARK ETFs Worth Your Attention Now
by Sweta Jaiswal, FRM
Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.
TDOCPositive Net Change PYPLPositive Net Change SQPositive Net Change ARKQPositive Net Change ARKWPositive Net Change ARKKPositive Net Change CRSPPositive Net Change ROKUPositive Net Change ARKGPositive Net Change GBTCNegative Net Change ARKFPositive Net Change
cloud-computing e-commerce etfs genetics internet
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Small-cap diagnostics player will grow sales 20%+ to over $310 million on COVID-19 testing and its mutations
VIVONegative Net Change HOLXNegative Net Change QDELPositive Net Change EDITPositive Net Change CRSPPositive Net Change
coronavirus genetics genomics medical
The Innovative Future Of ETFs
by Daniel Laboe
Ark Invest is driving a new generation of actively managed ETFs
TSLAPositive Net Change SQPositive Net Change ROKUPositive Net Change PRLBPositive Net Change NVTAPositive Net Change CRSPPositive Net Change ARKKPositive Net Change
biotechs etfs genetics software tech-stocks
Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers
by Sweta Jaiswal, FRM
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
PBENegative Net Change ARKGPositive Net Change GNOMPositive Net Change IDNAPositive Net Change
etfs genetics
Bear of the Day: Illumina (ILMN)
by Madeleine Johnson
The coronavirus pandemic has dampened this medical stock's earnings and outlook.
TMONegative Net Change ILMNPositive Net Change
genetics genomics
Bull of the Day: Quidel (QDEL)
by Kevin Cook
Multiple FDA approvals for new 15-minute COVID-19 antigen tests have estimates and shares rising sharply
QDELPositive Net Change MRNAPositive Net Change
biotechs genetics medical
Profit from the Genomics Market Momentum With These ETFs
by Sweta Jaiswal, FRM
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
GSKNegative Net Change PBENegative Net Change ARKGPositive Net Change GNOMPositive Net Change IDNAPositive Net Change
etfs genetics
Bull of the Day: Vertex Pharma (VRTX)
by Kevin Cook
While COVID-19 interrupts clinical trials, the champ of cystic fibrosis is about to repeat another year of 37% revenue growth
VRTXNegative Net Change CRSPPositive Net Change
biotechs genetics genomics medical pharmaceuticals